Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kastle Therapeutics, LLC
With
Ionis Pharmaceuticals, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Weight ≥ 50 kg
Diagnosis of Heterozygous Familial Hypercholesterolemia.
Females must be non-pregnant and non-lactating.
On stable lipid lowering therapy for at least 4 weeks.
Lipid levels meet the pre-specified criteria.
You may not be if
Subject had heart problems in the prior 6 months.
Subject has elevated ALT, AST, or CPK.
History of renal disease, liver disease, or malignancy.
Use of oral anticoagulants, unless the dose has been stable for 4 weeks
Have any other conditions, which in the opinion of the Investigator would make the subject unsuitable for enrollment, or could interfere with the subject participating in or completing the study.
Clareo Health | Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy
